The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study

Shaaban, Dalia; Al-Mutairi, Nawaf

doi:10.1080/09546634.2016.1254145

Cited by 18Psoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and Therapies

The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study

Open access

Shaaban, Dalia, Al-Mutairi, Nawaf·2018·Journal of Dermatological Treatment

DOI 10.1080/09546634.2016.1254145

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Psoriasis has been shown to be associated with increased incidence of myocardial infarction (MI). The data on the effect of tumor necrosis factor (TNF) inhibitors on MI in psoriasis are scarce. OBJECTIVE: To evaluate the effect of TNF inhibitors on the risk of MI in psoriasis patients compared with methotrexate (MTX) and topical agents. METHODS: Data were obtained from the Electronic Health Records database of Farwaniya Hospital from psoriasis patients seen from January 2008 to December 2014. Patients were categorized into TNF inhibitor, MTX and topical cohorts. RESULTS: The study included 4762 psoriasis patients. Both TNF inhibitor and MTX cohorts showed a statistically lower rate of MI compared with topical cohort. However, there was no statistically significant difference in MI rate between TNF inhibitor and MTX cohorts (P = .32). The probability of MI was lower in TNF inhibitor responders compared with non-responders (p = .001). CONCLUSIONS: The use of TNF inhibitors in psoriasis showed a significant reduction in the risk of MI compared with topical agents and a non-significant reduction compared with MTX. Responders to TNF inhibitor therapy showed a reduction in MI rate compared with non-responders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/09546634.2016.1254145

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Treatment with TNF inhibitors in psoriasis is associated with a decreased incidence of major adverse cardiac events.
“Treatment with TNF inhibitors in psoriasis is also associated with decreased incidence of major adverse cardiac events”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [188]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · see citing works
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315 · see citing works
Inflammation in Atherosclerosis
Libby, P. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179705 · Cited by 3,748 · see citing works
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Parisi, R., Symmons, D. P. M., Griffiths, C. E. M., & Ashcroft, D. M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.339 · Cited by 2,601 · see citing works
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899 · cited 1× · see citing works
“Patients with psoriasis have an increased risk of heart attacks, and this risk is independent of other major risk factors such as hypertension, diabetes, obesity, dyslipidemia and smoking, which are also commonly seen in patients of psoriasis (18).”
Background
Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects
Rotter, V., Nagaev, I., & Smith, U. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301977200 · Cited by 1,062 · see citing works
Prevalence of cardiovascular risk factors in patients with psoriasis
Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., Troxel, A. B., & Gelfand, J. M. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.08.040 · Cited by 1,010 · see citing works
Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis
Sattar, N. A., McCarey, D. W., Capell, H. A., & McInnes, I. B. (2003) · Circulation · doi:10.1161/01.cir.0000099844.31524.05 · Cited by 932 · see citing works
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907 · see citing works
Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome
Fernández-Real, J. M., & Ricart, W. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0010 · Cited by 886 · see citing works
Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.
Hotamisligil, G. S., Budavari, A., Murray, D., & Spiegelman, B. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117495 · Cited by 819 · see citing works
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
Mehta, N. N., Azfar, R. S., Shin, D. B., Neimann, A. L., Troxel, A. B., & Gelfand, J. M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp567 · Cited by 706 · see citing works
The Risk of Mortality in Patients With Psoriasis
Gelfand, J. M., Troxel, A. B., Lewis, J. D., Kurd, S. K., Shin, D. B., Wang, X., Margolis, D. J., & Strom, B. L. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.12.1493 · Cited by 536 · see citing works
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson, L., Turesson, C., Gülfe, A., Kapetanovic, M. C., Petersson, I. F., Saxne, T., & Geborek, P. (2005) · PubMed · Cited by 533 · see citing works
The Risk of Stroke in Patients with Psoriasis
Gelfand, J. M., Dommasch, E. D., Shin, D. B., Azfar, R. S., Kurd, S. K., Wang, X., & Troxel, A. B. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.112 · Cited by 441 · see citing works
Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients
Mallbris, L., Akre, O., Granath, F. N., Yin, L., Lindelöf, B., Ekbom, A., & Ståhle‐Bäckdahl, M. (2004) · European Journal of Epidemiology · doi:10.1023/b:ejep.0000020447.59150.f9 · Cited by 388 · see citing works
Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis
PRODANOWICH, S., MA, F., TAYLOR, J., PEZON, C., FASIHI, T., & KIRSNER, R. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.06.017 · Cited by 384 · see citing works
Psoriasis: a possible risk factor for development of coronary artery calcification
Ludwig, R. J., Herzog, C., Rostock, A., Ochsendorf, F. R., Zollner, T. M., Thaçi, D., Kaufmann, R., Vogl, T. J., & Boehncke, W. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07562.x · Cited by 374 · see citing works
Mechanisms of Disease: atherosclerosis in autoimmune diseases
Sherer, Y., & Shoenfeld, Y. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0092 · Cited by 357 · see citing works
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis
Greenberg, J. D., Kremer, J. M., Curtis, J. R., Hochberg, M. C., Reed, G., Tsao, P., Farkouh, M. E., Nasir, A., Setoguchi, S., & Solomon, D. H. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.129916 · Cited by 350 · see citing works
Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
Wu, J. J., Poon, K. T., Channual, J. C., & Shen, A. Y. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.2502 · Cited by 303 · see citing works
Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis
Kiortsis, D. N., Mavridis, A. K., Vasakos, S., Nikas, S. N., & Drosos, A. A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.026534 · Cited by 254 · see citing works
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
Popa, C. D., Netea, M. G., Radstake, T. R. D. J., der Meer, J. W. M. V., Stalenhoef, A. F. H., van Riel, P. L. C. M., & Barerra, P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.023119 · Cited by 224 · see citing works
Psoriasis and occlusive vascular disease
McDonald, C. J., & Calabresi, P. (1978) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1978.tb02012.x · Cited by 205 · see citing works
Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort
Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L. E., Lasthein, S., Lindhardsen, J., Kristensen, S. L., Torp-Pedersen, C. T., et al. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12768 · Cited by 191 · see citing works
Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a D anish real‐world cohort study
Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S. L., Iversen, L., Lasthein, S., Gniadecki, R., Dam, T. N., Torp-Pedersen, C. T., et al. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02593.x · Cited by 177 · see citing works
Comorbidities associated with psoriasis: An experience from the Middle East
Al-Mutairi, N., Al-Farag, S., Almutairi, A., & Alshiltawy, M. (2010) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2009.00777.x · Cited by 176 · see citing works
Self-citation
The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study
Abuabara, K., Lee, H., & Kimball, A. B. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10525.x · Cited by 126 · see citing works
Comorbidities in Psoriasis Patients
Kim, N., Thrash, B., & Menter, A. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.01.002 · Cited by 125 · see citing works
What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology
Dixon, W. G., & Symmons, D. P. M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.063867 · Cited by 122 · see citing works
Epidemiology of comorbidities in psoriasis
Naldi, L., & Mercuri, S. R. (2010) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2010.01304.x · Cited by 100 · see citing works
Inflammation, thrombosis and acute coronary syndromes
Carter, A. M. (2005) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2005.018 · Cited by 70 · see citing works
Long-Term Prognosis and Comorbidities Associated with Psoriasis in the Newfoundland and Labrador Founder Population
Gulliver, W. P. F., MacDonald, D., Gladney, N., Alaghehbandan, R., Rahman, P., & Baker, K. A. (2011) · Journal of Cutaneous Medicine and Surgery · doi:10.2310/7750.2010.10013 · Cited by 29 · see citing works
Mortality and Causes of Death among Psoriatics
Lindegard, B. (2009) · Dermatologica · doi:10.1159/000248321 · Cited by 23 · see citing works
Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease?
Churton, S., Brown, L., Shin, T. M., & Korman, N. J. (2014) · Drugs · doi:10.1007/s40265-013-0173-5 · Cited by 18 · see citing works
Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis
Wu, J. J., Liu, L., Asgari, M. M., Curtis, J. R., Harrold, L. R., Salman, C., & Herrinton, L. J. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12296 · Cited by 11 · see citing works
Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis
Wu, J. J., Rowan, C. G., Bebchuk, J. D., & Anthony, M. S. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.02.004 · Cited by 10 · see citing works
Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor‐treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis
Wu, J. J., Rowan, C. G., Bebchuk, J. D., & Anthony, M. S. (2015) · International Journal of Dermatology · doi:10.1111/ijd.12921 · Cited by 7 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

Mallbris L, Akre O, Granath F, et al. Increased risk for cardio- vascular mortality in psoriasis in patients but not in outpa- tients. Eur J Epidemiol. 2004;19:225-30.

Sorted by citations

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690 · see citing works
Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment
Hu, S. C., & Lan, C.-C. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102211 · Cited by 199 · see citing works
Thymus involution sets the clock of the aging T-cell landscape: Implications for declined immunity and tissue repair
Elyahu, Y., & Monsonego, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101231 · Cited by 91 · see citing works
Peanut skin extract ameliorates high-fat diet-induced atherosclerosis by regulating lipid metabolism, inflammation reaction and gut microbiota in ApoE−/− mice
Xu, M., Lv, C., Wang, H., Lu, Q., Ye, M., Zhu, X., & Liu, R. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111014 · Cited by 82 · see citing works
Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience
Sator, P. G. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622318772705 · Cited by 54 · see citing works
Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease
Pope, B. S., & Wood, S. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.031 · Cited by 41 · see citing works
Biologics for Reducing Cardiovascular Risk in Psoriasis Patients
Terui, H., & Asano, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031162 · Cited by 37 · see citing works
Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in Psoriasis
Packer, M. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.027 · Cited by 33 · see citing works
Psoriasis and Cardiovascular Disease: A Narrative Review
Martinez‐Moreno, A., Ocampo‐Candiani, J., & Garza‐Rodríguez, V. (2020) · Korean Journal of Family Medicine · doi:10.4082/kjfm.20.0053 · Cited by 24 · see citing works
Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics
Andújar, I., Esplugues, J. V., & García-Martínez, P. (2022) · Pharmaceuticals · doi:10.3390/ph15091101 · Cited by 19 · see citing works
Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis
Galajda, N. Á., Meznerics, F. A., Mátrai, P., Fehérvári, P., Lengyel, A., Kolonics, M. V., Sipos, Z., Kemény, L. V., Csupor, D., Hegyi, P. J., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19900 · Cited by 20 · see citing works
Psoriasis comorbid with atherosclerosis meets in lipid metabolism
Chen, L., Chen, H., Guo, S., Chen, Z., Yang, H., Liu, Y., Chen, X., Chen, X., Du, T., Long, X., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1308965 · Cited by 13 · see citing works
The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ni, R., Zheng, J., Varghese, J., & Kumar, B. (2024) · Cureus · doi:10.7759/cureus.60980 · Cited by 13 · see citing works
Telmisartan Lowers Elevated Blood Pressure in Psoriatic Mice without Attenuating Vascular Dysfunction and Inflammation
Wild, J., Schüler, R., Knopp, T., Molitor, M., Kossmann, S., Münzel, T. F., Daiber, A., Waisman, A., Wenzel, P., & Karbach, S. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174261 · Cited by 8 · see citing works
Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review
Son, M. T. H., Biloa, Y. J. M., Gouttefarde, P., Franck, T., Cizeron, G., Oriol, M., Maccari, F., Cinotti, É., Trombert‐Paviot, B., Bongué, B., et al. (2025) · JEADV Clinical Practice · doi:10.1002/jvc2.70134 · Cited by 1 · see citing works
Biological Drug Use in Patients with Psoriasis: Our Clinical Experiences
Nazik, H., Öztürk, P., & Mülayim, M. K. (2018) · Turkiye Klinikleri Journal of Dermatology · doi:10.5336/dermato.2018-62612 · Cited by 1 · see citing works
Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania
Indrisiunaite, E., Jonaitytė, I. R., Karmaziene, T., & Raudonis, T. (2026) · Medicina · doi:10.3390/medicina62050855
Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis
Rodriguez, L. F. M., Aristizabal, A. Z., & Padilla, J. D. V. (2026) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2026.501473

Authors: Shaaban, D., & Al-Mutairi, N.
Affiliations: Tanta University (EG)
Kuwait University (KW)
Corresponding author: Al-Mutairi, Nawaf
ORCID: Al-Mutairi, Nawaf
Venue: Journal of Dermatological Treatment
Publisher: Informa UK Limited
Published: 2017-11-17
Volume: 29
Issue: 1
Pages: 3-7
ISSN: 0954-6634 (ISSN-L)
1471-1753
DOI: 10.1080/09546634.2016.1254145
OpenAlex: W2551991877
Cited by: 18
References: 38
Citations by year: 2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 1
FWCI: 1.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.org/10.1080/policies-text-data-mining (tdm)
Locations: Journal of Dermatological Treatment (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords: psoriasis, tumor necrosis factor inhibitors, myocardial infarction, methotrexate, topical treatment, cardiovascular risk, treatment response, inflammatory skin diseases
MeSH terms: Etanercept, Adalimumab, Infliximab, Administration, Topical, Adult, Dermatologic Agents, Drug Therapy, Combination, Female, Humans, Male, Methotrexate, Middle Aged, Myocardial Infarction, Psoriasis, Retrospective Studies, Risk, Tumor Necrosis Factor-alpha, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks